Abstract 434: LDL Apheresis Significantly Alters HDL Cargo and Function in Familial Hypercholesterolemia Subjects

2014 ◽  
Vol 34 (suppl_1) ◽  
Author(s):  
Donald R Lynch ◽  
Carrie Wiese ◽  
Qi Liu ◽  
W H McDonald ◽  
Robert C Taylor ◽  
...  

In addition to cholesterol, HDL transports a wide-variety of cargo including vitamins, nucleic acids, and a diverse set of proteins. Outside of the reverse cholesterol transport pathway, HDL has alternative functions that contribute to its anti-atherogenicity, including anti-inflammatory, anti-oxidant, and signaling capacities. Recently, we found that HDL transports and delivers functional microRNAs to recipient cells, which likely confers HDL’s ability to suppress adhesion molecule expression in endothelial cells. As such, changes to HDL’s cargo impact many of these alternative functions, and thus its protective capacity. HDL dysfunction has been identified among patients with familial hypercholesterolemia (FH), an inherited disease due to mutations in the LDL receptor and associated with severe elevations in LDL-cholesterol (LDL-C) levels, which may necessitate LDL apheresis (LA) in management. Here we demonstrate that LA significantly alters HDL’s miRNA and protein signatures. We believe that these changes may have profound consequences on HDL’s protective capacity. Using density-gradient ultracentrifugation, we found 31 proteins to be significantly altered on HDL after LA, as determined by shotgun proteomics and multidimensional protein identification technology analysis. For example, vitamin D-binding protein (1.74-fold) was increased, while lipopolysaccharide-binding protein (-1.92-fold), platelet-activating factor acetylhydrolase (-2.06), and apolipoprotein A-V (-2.4-fold) were found to be decreased. Gene ontology and KEGG enrichment analysis demonstrated roles of these proteins in response to stress, coagulation, hemostasis, and vesicle-mediated transport. Fast-protein liquid chromatography was used to further purify HDL for miRNA profiling using TaqMan OpenArrays, and we found 8 HDL-miRNAs to be significantly altered -- 3 down (miR-302b -13.9-fold, miR-224 -1.8, miR-572 -2.4-fold) and 5 up (miR-7 9.8-fold, miR-208b 16.2-fold, miR-34a-3p 3-fold, miR-627 2.4-fold, miR-1183 4.8-fold). Both miR-302b and miR-224 decreased; these are miRNAs previously reported to suppress proliferation through targeting AKT2 and apoptosis, respectively. As such, these changes likely alter HDL’s function in FH subjects.

2015 ◽  
Vol 35 (suppl_1) ◽  
Author(s):  
Masahiro Koseki ◽  
Shizuya Yamashita

Familial hypercholesterolemia (FH) is an inherited disorder, mainly caused by defects in low-density lipoprotein (LDL) receptor gene. The patients are characterized by high LDL cholesterol levels in the blood and premature cardiovascular disease. Although most of heterozygous FH patients are usually treated with statin, ezetimibe and bile acid sequestrants, homozygous FH patients are resistant to drug therapy. Therefore, in Japan, many of homozygous FH patients are treated by LDL-apheresis. LDL-apheresis is a great procedure to remove LDL cholesterol from the blood and contribute to improve prognosis of homozygous FH patients. However, the effect of removing LDL cholesterol is temporary and still not enough. As a definitive therapy, liver transplantation therapy could be one of options to recover LDL receptor, but donor is limited in Japan. Therefore, based on the increase of the evidence about the safety of mesenchymal stem cells and percutaneous transhepatic portal approach in islet transplantation, we have developed a cell transplantation therapy with allogeneic adipose tissue-derived multilineage progenitor cells (ADMPCs), as an alternative treatment instead of liver transplantation. Our group has already proved that xenogenic transplantation of human ADMPCs into Watanabe heritable hyperlipidemic rabbits resulted in significant reductions in total cholesterol, and the reductions were observed within 4 weeks and maintained for 12 weeks. These results suggested that hADMPC transplantation could correct the metabolic defects and be a novel therapy for inherited liver diseases. Here, we report a protocol for the first-in-human clinical trial, which has been approved by the institutional review board and Ministry of Health, Labour and Welfare, Japan.


2014 ◽  
Vol 34 (suppl_1) ◽  
Author(s):  
Donald R Lynch ◽  
Deborah A Winegar ◽  
Margery Connelly ◽  
Patricia G Yancey ◽  
Ray Pourfarzib ◽  
...  

Background: Familial Hypercholesterolemia is an inherited disease characterized by severely elevated levels of LDL cholesterol (LDL-C) and associated with premature coronary artery disease (CAD). LDL apheresis (LA) is indicated for management of CAD patients with LDL-C>200 mg/dl despite medical therapy. LA may reduce LDL-C concentrations by up to 70%; this in turn has been associated with regression of atherosclerosis. NMR measurement of signals corresponding to methyl group protons of glycoproteins (GlycA and GlycB) has recently been validated in prediction of atherosclerosis and chronic systemic inflammation. Studies have demonstrated a reduction in inflammatory cytokines with LA, but no study to date has evaluated the impact of LA on levels of glycoproteins as markers of chronic inflammation. Objective: To determine the effect of LA on plasma levels of glycoproteins using a novel NMR based technique, and to correlate these findings with changes in lipoprotein subclasses. Methods: Comprehensive NMR lipoprotein analysis was performed on serum obtained from seven subjects prior to and following LA sessions performed at two-week intervals (N = 47 paired samples). Three subjects had homozygous FH, three had heterozygous FH with CAD and/or LDL-C > 200 mg/dL, one patient had severe mixed dyslipidemia with CAD and LDL-C > 200 mg/dL. Results: Mean GlycA and GlycB levels were 335±91 μmol/L and 125±31 μmol/L respectively prior to LA. Following LA treatment, there was a significant reduction in GlycA to 277±73 μmol/L (P<0.001) and in GlycB to 102±28 μmol/L (P<0.001). The reduction in GlycA was strongly correlated with a decrease in total small LDL particle number (r = 0.68, p < 0.001) and with a reduction in medium VLDL particle number (r = 0.52, P < 0.001). GlycB level was weakly correlated with small LDL (r = 0.39, P = 0.007) and IDL particle numbers (r = 0.32, P = 0.028). In addition, GlycA and GlycB levels were correlated to each other (r = 0.49, P < 0.001). Conclusion: This is the first report of NMR detection of glycoproteins as inflammatory biomarkers in patients with severe dyslipidemia undergoing LA. LA was associated with a significant reduction in levels of both GlycA and GlycB, which correlated with reductions in LDL and VLDL particle number.


Biomedicines ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 1073
Author(s):  
Alessandro Di Minno ◽  
Roberta Clara Orsini ◽  
Mattia Chiesa ◽  
Viviana Cavalca ◽  
Ilenia Calcaterra ◽  
...  

Introduction: Familial hypercholesterolemia (FH) is characterized by extremely high levels of circulating low-density lipoprotein cholesterol (LDL-C) and is caused by mutations of genes involved in LDL-C metabolism, including LDL receptor (LDLR), apolipoprotein B (APOB), or proprotein convertase subtilisin/Kexin type 9 (PCSK9). Accordingly, PCSK9 inhibitors (PCSK9i) are effective in LDL-C reduction. However, no data are available on the pleiotropic effect of PCSK9i. To this end, we performed an untargeted metabolomics approach to gather a global view on changes in metabolic pathways in patients receiving treatment with PCSK9i. Methods: Twenty-five FH patients starting treatment with PCSK-9i were evaluated by an untargeted metabolomics approach at baseline (before PCSK9i treatment) and after 12 weeks of treatment. Results: All the 25 FH subjects enrolled were on maximal tolerated lipid-lowering therapy prior to study entry. After a 12 week treatment with PCSK9i, we observed an expected significant reduction in LDL-cholesterol levels (from 201.0 ± 69.5 mg/dL to 103.0 ± 58.0 mg/dL, p < 0.001). The LDL-C target was achieved in 36% of patients. After peak validation and correction, after 12 weeks of PCSK9i treatment as compared to baseline, we observed increments in creatine (p-value = 0.041), indole (p-value = 0.045), and indoleacrylic acid (p-value= 0.045) concentrations. Conversely, significant decreases in choline (p-value = 0.045) and phosphatidylcholine (p-value < 0.01) together with a reduction in platelet activating factor (p-value = 0.041) were observed. Conclusions: Taking advantage of untargeted metabolomics, we first provided evidence of concomitant reductions in inflammation and platelet activation metabolites in FH patients receiving a 12 week treatment with PCSK9i.


2020 ◽  
Vol 4 (1) ◽  
pp. 1-6
Author(s):  
Karin Littmann ◽  
Karolina Szummer ◽  
Hannes Hagström ◽  
Karoly Dolapcsiev ◽  
Jonas Brinck ◽  
...  

Abstract Background Homozygous familial hypercholesterolaemia (FH) is an autosomal-dominant inherited disease presenting with highly elevated low-density lipoprotein cholesterol (LDL-C) levels. Untreated, the patient can develop atherosclerosis and cardiovascular disease already in adolescence. Treatment with statins and ezetimibe is usually not sufficient and LDL apheresis is often required. Lomitapide, an inhibitor of the microsomal triglyceride transfer protein, reduces LDL-C and triglyceride levels and can be used alone or in combination with other therapies in homozygous FH. However, experience with this agent is still limited. Case summary We present a young female who was diagnosed with homozygous FH at 6 years of age. She shows a complete lack of normal LDL receptor activity and no cholesterol-lowering effect from statins. The patient was treated with LDL apheresis from 7 years of age. When LDL apheresis treatment extended to twice a week, she began to experience adverse effects, including catheter-related complications, infections, and hospital admissions. When lomitapide treatment was initiated, the frequency of apheresis reduced, the LDL-C levels improved and she has not had any further hospital admissions since. Initially, she suffered from gastrointestinal disturbances. However, after 3 years of treatment with lomitapide 20 mg/day, the patient has not experienced any adverse effects. Discussion In this female with homozygous FH adding lomitapide treatment to LDL apheresis has contributed to improved LDL-C levels, a reduction in LDL apheresis sessions and enhanced quality of life. No adverse effects have been reported. These findings suggest that lomitapide can be a drug of choice in patients with homozygous FH.


1997 ◽  
Vol 43 (3) ◽  
pp. 427-435 ◽  
Author(s):  
Steve E Humphries ◽  
Vilmundur Gudnason ◽  
Ros Whittall ◽  
Ian N M Day ◽  

Abstract The identification of the specific mutation causing an inherited disease in a patient is the framework for the development of a rationale for therapy and of DNA-based tests for screening relatives. We present here a review of the single-strand conformational polymorphism (SSCP) method, which allows DNA fragments that have been amplified with specific primers and PCR to be scanned rapidly for any sequence variation. The general principles of the method are described, as are the major factors that must be considered in developing an optimal SSCP strategy, namely the length of the PCR fragment and the temperature of the gel run. Options for sample denaturing gel characteristics and detection of DNA fragments are discussed. In addition, several modifications are presented that have been developed for high-throughput mutational analysis. The application of these techniques to screen for mutations in the LDL receptor gene in patients with familial hypercholesterolemia are described.


Sign in / Sign up

Export Citation Format

Share Document